Third Wave Technologies has announced the expansion of its clinical product to include Invader® DNA analyte specific reagents for mutations in the cystic fibrosis (CF) gene. Both the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) have recommended that all couples seeking preconception or prenatal care be screened for 25 CF gene mutations. The Invader® CF reagents will allow CLIA high-complexity laboratories to create Invader® CF screening panels in accordance with the ACMG and ACOG recommendations.
The fundamental competitive advantages of Third Wave's Invader® Technology are its ease of use, accuracy, and costeffectiveness. The Invader® technology is transforming both how and where genetic analysis can be performed. Traditional PCR genetic analysis methods require time-consuming, specialized labor on dedicated, expensive equipment in a tightly controlled setting. The Invader® technology is a simpler, more accurate solution that enables any size CLIA highcomplexity laboratory to provide patient results more quickly, increase throughput, and lower costs.
The "New Products" page is designed to offer you news and information from businesses serving the genetics community. We welcome your submissions. All submissions are subject to review by the Editor. For more information, contact Al Lucchesi, National Accounts Manager, Lippincott Williams & Wilkins, 530 Walnut Street, Philadelphia, PA 19106; phone 215-521-8409; fax 215-521-8411; email alucches@lww.com. 
